Pharmacally
Disease & Drugs
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Disease & Drugs
Clinical TrialsLilly’s Foundayo Improves OSA Severity in PAP and Non-PAP UsersLilly’s oral GLP-1 receptor agonist Foundayo (orforglipron) demonstrated significant reductions in obstructive sleep apnoea severity across two Phase 3 ATTAIN-OSA studies, with improvements in breathing interruptions, hypoxic burden…Fact-Checked
Clinical TrialsGilead Reports Higher PrEP Persistence with Lenacapavir in PURPOSE 5Gilead Sciences reported significantly higher one-year HIV prevention persistence with twice-yearly injectable lenacapavir than daily oral F/TDF in its Phase 2 PURPOSE 5 trial.Fact-Checked
Clinical TrialsUCB and Biogen Report Positive Lupus Findings for DapirolizumabUCB and Biogen reported higher TRM-SLE response rates with investigational dapirolizumab pegol versus placebo in post-hoc analyses of the Phase 3 PHOENYCS GO trial.Fact-Checked
Clinical TrialsNovo Nordisk Reports Improved Fibrosis Markers With Wegovy in MASHNovo Nordisk reported improvements in liver injury, disease activity and several fibrosis markers with Wegovy (semaglutide) 2.4 mg in a post hoc analysis of 106 adults with MASH…Fact-Checked
Drugs Safety AlertNovartis’ Zolgensma Raises New Tumorigenicity Concerns After FDA FindingsFDA is investigating a potential malignancy risk associated with Zolgensma after identifying three GLI1-associated tumor cases, including two with confirmed AAV vector DNA integration.Fact-Checked
Clinical Trialsargenx Meets Phase III Endpoint With Efgartigimod in Autoimmune MyositisThe Phase III ALKIVIA trial met its primary endpoint, demonstrating significant improvement with efgartigimod in patients with autoimmune myositis.Fact-Checked
Clinical TrialsCullinan Reports 4 Renal Responses With Velinotamig in Lupus StudyInterim Phase 1b/2a findings presented at ACR Convergence 2026 show that velinotamig achieved reported complete renal response thresholds in four patients within 24 weeks, while eight of nine…Fact-Checked
Clinical TrialsAulos Reports 9.1-Month PFS with Imneskibart in MelanomaAulos Bioscience reports Phase 2 findings for imneskibart combinations in checkpoint inhibitor-refractory melanoma and NSCLC.Fact-Checked
Clinical TrialsObsidian’s Amsoki-cel Shows 67% ORR in ICI-Resistant MelanomaObsidian Therapeutics reported a 67% objective response rate with investigational TIL therapy amsoki-cel in ICI-resistant advanced melanoma.Fact-Checked
Clinical TrialsGilead Reports 75.4% ALP Normalization With Livdelzi in IDEAL TrialGilead’s Phase 3 IDEAL study found that 75.4% of patients receiving Livdelzi (seladelpar) achieved the ALP normalization composite endpoint at Week 52, compared with 16.1% on placebo.Fact-Checked
New Drug ApprovalPharming Gains MHRA Clearance for Paediatric Joenja Use in APDSThe MHRA has expanded Pharming’s Joenja (leniolisib) indication to children aged 4–11 years with activated PI3K delta syndrome (APDS) weighing at least 27 kg.Fact-Checked
Clinical TrialsAkeso Reports Strong Pathological Responses With Ivonescimab in NSCLCAkeso’s Phase II study published in Nature Medicine reports a 70.1% major pathological response and 50.7% pathological complete response with perioperative ivonescimab plus chemotherapy in resectable NSCLC.Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.